Skip to main content
. 2022 Jan 6;42(1):BSR20211783. doi: 10.1042/BSR20211783

Figure 2. UALCAN and GEPIA-based correlation analysis of MTHFD1L overexpression with the OS of distinct cancer patients.

Figure 2

(A) UALCAN-based correlation analysis of MTHFD1L overexpression with the OS of BLCA, HNSC, KIRP, LUAD, and UCEC patients, and (B) GEPIA-based correlation analysis of MTHFD1L overexpression with the OS of BLCA, HNSC, KIRP, LUAD, and UCEC patients. A P-value (<0.05) was considered as statistically significant.